# Cocrystal Pharma, Inc.: overview COCP · Nasdaq · CIK 1412486 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cocp.md) · [Financials](/companies/cocp/financials.md) · [Filings](/companies/cocp/filings.md) · [Insiders](/companies/cocp/insiders.md) Latest reported revenue: [$105.0k](/filings/0001493152-26-037573.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-037573). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | [225](/filings/0001493152-26-023377.md) | [105](/filings/0001493152-26-037573.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(1047.1%)](/filings/0001493152-26-023377.md) | [(3032.4%)](/filings/0001493152-26-037573.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(1021.8%)](/filings/0001493152-26-037573.md) | [(3013.3%)](/filings/0001493152-26-037573.md) | | Diluted EPS | $ per share | [(0.49)](/filings/0001493152-25-022581.md) | not reported | [(0.23)](/filings/0001493152-26-023377.md) | [(0.20)](/filings/0001493152-26-037573.md) | [(0.19)](/filings/0001493152-25-022581.md) | not reported | [(0.17)](/filings/0001493152-26-023377.md) | [(0.23)](/filings/0001493152-26-037573.md) | | Free cash flow | $k | [(5,123) d](/filings/0001493152-25-022581.md) | [(3,160) d](/filings/0001493152-26-013838.md) | not reported | not reported | not reported | [(1,736) d](/filings/0001493152-26-013838.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.16)](/filings/0001493152-22-007551.md) | [(4.77)](/filings/0001493152-24-011613.md) | [(1.87)](/filings/0001641172-25-001496.md) | [(1.72)](/filings/0001493152-26-013838.md) | [(0.78)](/filings/0001493152-26-013838.md) | | Free cash flow | $m | [(12.8)](/filings/0001493152-23-009385.md) | [(21.5)](/filings/0001493152-24-011613.md) | [(14.8)](/filings/0001641172-25-001496.md) | [(16.5)](/filings/0001493152-26-013838.md) | [(8.2)](/filings/0001493152-26-013838.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cocp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $376.1k | 358,228 | | Added +118,257 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $188.6k | 179,628 | | Added +55,700 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $184.1k | 175,379 | | New +175,379 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $80.0k | 76,208 | | Reduced −14,023 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $77.4k | 73,746 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $47.4k | 45,118 | | New +45,118 | | [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $33.5k | 31,886 | | Unchanged | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $30.8k | 29,342 | | Reduced −6,689 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $27.0k | 25,761 | | Added +13,050 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $25.2k | 24,016 | | Unchanged | ## Recent filings [All 654 filings](/companies/cocp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 08:00 ET | [8-K](/filings/0001493152-26-041877.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041877 | | 2026-08-18 | 16:30 ET | [8-K](/filings/0001493152-26-039023.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-039023 | | 2026-08-17 | 16:15 ET | [8-K](/filings/0001493152-26-038747.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-038747 | | 2026-08-13 | 07:29 ET | [10-Q](/filings/0001493152-26-037573.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037573 | | 2026-08-07 | 17:11 ET | [SCHEDULE 13D/A](/filings/0001493152-26-036650.md) | Ownership report, active investor, amended | 0001493152-26-036650 | | 2026-08-03 | 07:15 ET | [8-K](/filings/0001493152-26-035743.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-035743 | | 2026-07-17 | 08:00 ET | [8-K](/filings/0001493152-26-033662.md) | 5.07 Shareholder vote results | 0001493152-26-033662 | | 2026-06-09 | 07:00 ET | [8-K](/filings/0001493152-26-027837.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001493152-26-027837 | | 2026-06-03 | 07:00 ET | [8-K](/filings/0001493152-26-026965.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-026965 | | 2026-05-27 | 16:30 ET | [DEF 14A](/filings/0001493152-26-025428.md) | Proxy statement, period 2026-05-27 | 0001493152-26-025428 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013838.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9c5cbb7c-1148-4b64-acb4-30f73ec8df84) ## About the filer - CIK: 1412486 - Tickers: COCP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.